EYD-001(EydisBio)

N/A

Report date: 2025/10/22 16:59:50
NMEFirst In Class

Base Information

Drug NameEYD-001(EydisBio)
Drug Alias Name(E)-N-(6-(piperidin-1-ylmethyl)-1-propyl-1,3-dihydro-2H-benzo[d]imidazol-2-ylidene)isophthalamideEYD-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTGF-β activated kinase-1 inhibitors
TargetsTGF-β activated kinase-1
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPeripheral Nerve Injuries +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEydisBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesEydisBio Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPeripheral Nerve Injuries +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A